BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of July 8, 2026, BCRX trades at $10.81 with a market cap of $2.58B and a P/E ratio of -5.92. BCRX moved -1.60% today. Year to date, BCRX is +43.47%; over the trailing twelve months it is +25.46%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $24.14. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
8 analysts cover BCRX: 0 strong buy, 8 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $24.14.
| Metric | Value |
|---|---|
| Price | $10.81 |
| Market Cap | $2.58B |
| P/E Ratio | -5.92 |
| EPS | $-1.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.31 |
| 52-Week Low | $6.00 |
| Volume | 4.25K |
| Avg Volume | 0 |
| Revenue (TTM) | $885.72M |
| Net Income | $-457.98M |
| Gross Margin | 97.75% |
8 analysts cover BCRX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.14.